影响多发性骨髓瘤预后的分子生物学异常研究进展
Research advances in molecular biological abnormalities affecting the prognosis of multiple myeloma
李妙雨 1高娅娅 2高广勋1
作者信息
- 1. 解放军空军军医大学西京医院血液内科,陕西 西安 710032
- 2. 陕西中医药大学,陕西 咸阳 712046
- 折叠
摘要
多发性骨髓瘤(multiple myeloma,MM)是一种以单克隆浆细胞异常增生和多灶性骨骼受累为特征的浆细胞肿瘤,多发于中老年人.随着免疫靶向治疗的飞速发展,可用于MM患者的治疗药物及联合方案越来越多样化,MM目前仍不可治愈.近些年由于核型分析、荧光原位杂交技术、流式细胞术、液体活检等分子生物学检测技术的广泛应用,MM的诊断率大为提高.同时,许多与MM预后相关的基因异常先后被发现.本文旨在总结已知的分子生物学异常与MM预后的关系,为MM患者的诊断、治疗及预后提供新的信息.
Abstract
Multiple myeloma is a plasma cell tumor characterized by monoclonal plasma cell dysplasia and multifocal bone in-volvement.It mainly occurs in middle-aged and elderly people.Although proteasome inhibitors,immunomodulators and hemato-poietic stem cell transplantation have improved the survival rate of patients,MM is still incurable.In recent years,due to the wide application of molecular biological detection technologies such as karyotype analysis,FISH,flow cytometry,liquid biopsy,etc.,the diagnostic rate of MM has been greatly improved.At the same time,many gene abnormalities related to the prognosis of MM have been found successively.
关键词
多发性骨髓瘤/基因异常/预后Key words
Multiple myeloma/Genetic abnormality/Prognosis引用本文复制引用
基金项目
国家自然科学基金项目(81970190)
陕西省社发公关重点项目(2019ZDLSF02-02)
国家医学中心转化课题(2020ZKMC01)
出版年
2024
国家科技期刊平台
NSTL
万方数据